why Vascular Biogenics Ltd. [VBLT] is a Good Choice for Investors After New Price Target of $5.00

Vascular Biogenics Ltd. [NASDAQ: VBLT] traded at a high on 08/08/22, posting a 6.55 gain after which it closed the day’ session at $0.25. The company report on August 2, 2022 that VBL Therapeutics Announces Workforce Reduction.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve capital. As a result, VBL will reduce its workforce by approximately 35%. As part of the cost cutting initiatives, Dr. Ron Cohen, Dr. Bennett Shapiro and Ms. Alison Finger resigned from the board of directors, effective August 1, 2022.

“I would like to express my sincere thanks to our employees who are being affected by this decision,” said Prof. Dror Harats, M.D., chief executive officer of VBL Therapeutics. “We are grateful for their dedication and contributions to our efforts to bring a new treatment to cancer patients in need. This is a necessary step we must take in order to streamline operations, secure our financial position and execute on our plan. I would also like to thank our outgoing board members Ron, Ben and Alison for their service to VBL.”.

The results of the trading session contributed to over 8392877 shares changing hands. Over the past one week, the price volatility of Vascular Biogenics Ltd. stands at 10.81% while the volatility over the past one month is 13.07%.

The market cap for VBLT stock reached $17.97 million, with 77.39 million shares outstanding and 52.74 million shares in the current float. Compared to the average trading volume of 2.43M shares, VBLT reached a trading volume of 8392877 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Vascular Biogenics Ltd. [VBLT]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VBLT shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VBLT stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Oppenheimer have made an estimate for Vascular Biogenics Ltd. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on July 20, 2022. The new note on the price target was released on July 20, 2022, representing the official price target for Vascular Biogenics Ltd. stock. Previously, the target price had yet another raise to $5.50, while Oppenheimer analysts kept a Outperform rating on VBLT stock.

The Average True Range (ATR) for Vascular Biogenics Ltd. is set at 0.12, with the Price to Sales ratio for VBLT stock in the period of the last 12 months amounting to 25.67. The Price to Book ratio for the last quarter was 0.46, with the Price to Cash per share for the same quarter was set at 0.62.

How has VBLT stock performed recently?

Vascular Biogenics Ltd. [VBLT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.95. With this latest performance, VBLT shares dropped by -87.65% in over the last four-week period, additionally sinking by -79.84% over the last 6 months – not to mention a drop of -88.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBLT stock in for the last two-week period is set at 23.97, with the RSI for the last a single of trading hit 20.71, and the three-weeks RSI is set at 27.47 for Vascular Biogenics Ltd. [VBLT]. The present Moving Average for the last 50 days of trading for this stock 1.2789, while it was recorded at 0.2407 for the last single week of trading, and 1.6262 for the last 200 days.

Vascular Biogenics Ltd. [VBLT]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Vascular Biogenics Ltd. [VBLT] shares currently have an operating margin of -3905.73 and a Gross Margin at -111.07. Vascular Biogenics Ltd.’s Net Margin is presently recorded at -3895.83.

Return on Equity for this stock declined to -72.01, with Return on Assets sitting at -56.26.

Vascular Biogenics Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.20 and a Current Ratio set at 4.20.

Insider trade positions for Vascular Biogenics Ltd. [VBLT]

There are presently around $2 million, or 20.60% of VBLT stock, in the hands of institutional investors. The top three institutional holders of VBLT stocks are: LION POINT CAPITAL, LP with ownership of 2,593,286, which is approximately 0% of the company’s market cap and around 23.95% of the total institutional ownership; PHOENIX HOLDINGS LTD., holding 1,020,000 shares of the stock with an approximate value of $0.26 million in VBLT stocks shares; and IKARIAN CAPITAL, LLC, currently with $0.21 million in VBLT stock with ownership of nearly 5.046% of the company’s market capitalization.

Positions in Vascular Biogenics Ltd. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 14 institutional holders increased their position in Vascular Biogenics Ltd. [NASDAQ:VBLT] by around 326,937 shares. Additionally, 7 investors decreased positions by around 93,273 shares, while 10 investors held positions by with 6,079,379 shares. The mentioned changes placed institutional holdings at 6,499,589 shares, according to the latest SEC report filing. VBLT stock had 6 new institutional investments in for a total of 130,278 shares, while 3 institutional investors sold positions of 29,341 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here